A Phase I Study of CC-92480 and Dexamethasone for Patients with Recurrent or Persistent Multiple Myeloma

Full Title

A Phase 1 Multicenter, Open-Label Study to Assess the Safety, Pharmacokinetics and Preliminary Efficacy of CC-92480 in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma

Purpose

The purpose of this study is to assess the safety of treatment with the investigational drug CC-92480 in combination with dexamethasone for patients with multiple myeloma that has come back or continued to grow despite standard therapy. CC-92480 is a type of drug called a “cereblon-modifying (CM) agent.”

Other CM agents used to treat multiple myeloma include thalidomide, lenalidomide, and pomalidomide. CC-92480 is a new CM agent that is thought to be more effective for targeting and destroying proteins that help to produce myeloma cells. The effect of CC-92480 may be increased when it is used in combination with dexamethasone, a standard part of myeloma treatment. Both CC-92480 and dexamethasone are taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma that continued to grow or came back despite prior treatment that included a proteasome inhibitor (bortezomib or carfilzomib) and a CM agent.
  • At least 4 weeks must pass between the completion of prior therapies and entry into the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Ola Landgren at 212-639-5126.

Protocol

17-622

Phase

I

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators